Brought to you by 
Genentech chooses two targets in antibody deal with Adimab
21 Dec 2010
Executive Summary
In one of three deals it announced on the same day, Adimab Inc. (mAbs) agreed to produce fully human antibodies against two targets chosen by Roche's Genentech Inc. Adimab's alliance triplet also included separate collaborations with Eli Lilly and Human Genome Sciences.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech chooses two targets in antibody deal with Adimab
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice